Technical Details:
Decoy lymphotoxin beta receptor (LT? has potent immune inhibitory activities, and thus represents a promising biologic for the treatment of inflammation, autoimmune diseases and graft-versus-host disease (GVHD). As this reagent interrupts multiple molecular interactions, including LT?T?and LIGHT-HVEM/LT? underlying molecular mechanisms have yet to be fully understood. Scientists at JHU have now determined that blockade of the LIGHT-HVEM pathway is sufficient to induce amelioration of GVHD in mouse models and illustrate a novel target for selective immunotherapy in allogeneic bone marrow transplantation.
Looking for Partners:
GVHD is a common complication of allogeneic bone marrow transplantation and both acute and chronic forms remain difficult to treat. The novel mechanism of GVHD elucidated in the invention described will serve as a target for therapeutic intervention.
